Expert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.
Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Advertisement
Articles by Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Pankit Vachhani, MD, guides a discussion on the FDA approval of fedratinib and reviews how it has affected the therapeutic landscape for patients with primary myelofibrosis.
MPN expert Srdan Verstovsek, MD, PhD, shares insights into the role of ruxolitinib for the treatment of myelofibrosis.
An expert in the management of myeloproliferative neoplasms, Jamile Shammo, MD, FASCP, FACP, leads a discussion on best practices for assessing response and monitoring for progression.
Pankit Vachhani, MD, reviews recent changes to the NCCN Guidelines, highlighting the addition of luspatercept for the treatment of primary myelofibrosis.
Key opinion leaders in the management of myeloproliferative neoplasms review factors to consider when selecting treatments for patients and highlight the role of fedratinib in the first- or second-line settings.
A panel of experts in myeloid malignancies begins with a discussion on risk assessment criteria, next-generation sequencing, and symptom burden questionnaires to assess prognosis for patients with myelofibrosis.
Advances in the Management of MPNs
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Essential Thrombocythemia: Treatment Optimization
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Classifying Patients With Essential Thrombocythemia
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Primary Myelofibrosis: Trials of Interest
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
JAK2 Inhibitor Selection for Primary Myelofibrosis
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Fedratinib for Primary Myelofibrosis
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Ruxolitinib and Surgical Interventions
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Ruxolitinib for Primary Myelofibrosis
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Treating Intermediate/High-Risk Primary Myelofibrosis
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Management of Low-Risk Primary Myelofibrosis
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Primary Myelofibrosis: Risk Stratification
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: PROUD-PV Trial
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Utilization of Ruxolitinib for Polycythemia Vera
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: Ruxolitinib Trial Data
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: Switching Therapy
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Treatment Options for High-Risk Polycythemia Vera
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Management of Low-Risk Polycythemia Vera
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: Monitoring Patients
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: Risk Assessment
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: Prognostic Markers
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: Bone Marrow Biopsies
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: Diagnostic Work-up
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Characterization of Myeloproliferative Neoplasms
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Advertisement
Latest Updated Articles
Recent Updates to NCCN Guidelines on MF TreatmentPublished: July 6th 2021 | Updated:
- Bone Marrow Transplant for Patients With MF
Published: July 20th 2021 | Updated:
Monitoring Disease Response or Progression in MFPublished: July 6th 2021 | Updated:
Fedratinib for Patients With Primary MyelofibrosisPublished: July 13th 2021 | Updated:
Ruxolitinib for Patients With Primary MyelofibrosisPublished: July 13th 2021 | Updated:
Primary Myelofibrosis: Trials of InterestPublished: July 7th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5